Trial · NCT02482129
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Responders at Day 15 | Baseline (Day 1), Day 15 | This analysis population includes all subjects who received any study drug, had at least 1 post-baseline efficacy assessment, had no critical protocol deviations, and had a valid determination of response status for the primary endpoint (Per Protocol Analysis Set). | Participants | COUNT_OF_PARTICIPANTS |
| PRIMARY | Mean Best Corrected Visual Acuity (BCVA) at Each Visit | Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29 | This analysis population includes all subjects who received any study drug (Safety Analysis Set). Number Analyzed is the number of subjects with data at visit. | letters | MEAN |
| PRIMARY | Mean Intraocular Pressure (IOP) at Each Visit | Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29 | Safety Analysis Set. Number Analyzed is the number of subjects with data at visit. | mmHg | MEAN |
| PRIMARY | Number of Subjects With Increase From Baseline in Slit Lamp Parameters at Any Post-Treatment Visit | Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29 | Safety Analysis Set | participants | NUMBER |
| PRIMARY | Number of Subjects With an Increase From Baseline in Dilated Fundus Parameters at Any Post-Treatment Visit | Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29 | Safety Analysis Set | participants | NUMBER |
| SECONDARY | Number of Subjects With IOP Change From Baseline to Last On-Treatment Assessment | Baseline (Day 1), Up to Day 29 | Safety Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mean Change From Baseline in BCVA at Each Visit | Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29 | Safety Analysis Set. Number Analyzed is the number of subjects with data at visit. | letters | MEAN |
| SECONDARY | Time-to-Response | Baseline (Day 1), Up to Day 15 | Per Protocol Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Use of Rescue Treatment | Day 4, Day 8, Day 15 | Per Protocol Analysis Set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Mean Serum Concentration of Total LME636 at Each Visit | Baseline (Day 1), Day 4, Day 8, Day 15, Day 22, Day 29 | This analysis population includes all subjects who received investigative product (IP) and had at least 1 evaluable serum sample following IP exposure.(Pharmacokinetics Analysis Set). Number Analyzed is the number of subjects with data at visit. | ng/mL | MEAN |
| SECONDARY | Number of Subjects With Anti-LME636 Antibodies Present at Each Visit | Day 1, Day 4, Day 8, Day 15, Day 22, Day 29 | This analysis population includes all subjects with available immunogenicity data and no protocol deviations with relevant impact on the data (Immunogenicity Set). | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02482129/outcomes